Upcoming events – Obseva's first fibroid foray and Newron's test in Retts

Welcome to your weekly roundup of approaching clinical readouts. In the fourth quarter Obseva will see data from the first of two phase III trials of its gonadotropin-releasing hormone (GnRH) antagonist linzagolix in uterine fibroids.